

Pan Mersey Area Prescribing Committee

14:00 – 16:00 hours
Wednesday 23rd May 2018
The Education Centre, Kent Lodge,
Broadgreen Hospital, Thomas Drive, Liverpool, L14 3LB

Minutes

Members	Organisation(s)	Present
Peter Johnstone (Chair)	Prescribing Commissioner – Liverpool CCG	X
Dr Sid McNulty (Deputy Chair)	Consultant Endocrinologist/Chair Drug & Therapeutics Committee St Helens & Knowsley Teaching Hospitals NHS Trust	X
David Ainscough	Pharmacist, Mersey Care, Liverpool and South Sefton Community Services Division	X
Anna Atkinson	Deputy Lead Pharmacist Medicines Management, Lancashire Care NHS Foundation Trust	X
Catrin Barker	Chief Pharmacist - Alder Hey Children's NHS Foundation Trust	X
Dr Rob Barnett	LMC Representative, Liverpool	
Carolyn Barton	Pharmacist, Knowsley CCG	X
Nicola Baxter	Head of Medicines Optimisation, West Lancs CCG	
Colin Brennan	Deputy Clinical Services Manager/Surgical Division Lead Pharmacist, University Hospital Aintree	
Dr Ivan Camphor	Mid-Mersey LMC Representative	
Nicola Cartwright	Head of Medicines Management – St Helens CCG	
Marianne Charlton	Lead Pharmacist Medicines Management, Wirral University Teaching Hospital NHS Foundation Trust	X
Neil Chilton	Medicine Management Clinical Services Manager North West Boroughs Healthcare NHS Foundation Trust	
Nigel Cosford	Pharmacist, St Helens CCG	X
Dr Anna Ferguson	GP Clinical Lead – South Sefton CCG	X
Dr Claire Forde	CCG Governing Body Member, Prescribing Lead – Halton CCG	X
Donna Gillespie-Greene	Head of Medicines Commissioning Midlands & Lancashire Commissioning Support Unit	X
Gillian Gow	Chief Pharmacist – Liverpool Heart and Chest FT	X
Dr Jamie Hampson	GP, Liverpool CCG	X
Catherine Harding	Lead Pharmacist, Lancashire Care NHS FT	
Dr Dan Hawcutt	Consultant Paediatrician and Chair of D&T Alder Hey Children's NHS FT	X
Dr Adit Jain	Clinical Lead, Prescribing – Knowsley CCG	X
Dr Saket Jalan	GP Prescribing Lead, Wirral CCG	X
Jenny Jones	Principal Pharmacist Medicines Management Warrington & Halton Hospitals NHS FT	X
Jenny Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management Warrington CCG	X
Susanne Lynch	CCG Lead Medicines Management South Sefton CCG and Southport & Formby CCG	X
Paul Mooney	Deputy Chief Pharmacist/Medication Safety Officer, Liverpool Women's NHS Foundation Trust	
Dr Shankara Nagaraja	Consultant Intensivist/Anaesthetist, University Hospital Aintree	X



Rachael Pugh	Prescribing Advisor, Wirral Medicines Management Team, MLCSU	X
Sarah Quinn	Head of Medicines Management, Bridgewater Community Healthcare NHS Foundation Trust	
Kathryn Phillips	Pharmacist, Bridgewater Community Healthcare NHS Foundation Trust	X
Lucy Reid	Lead Pharmacist - Halton CCG Locality Medicines Management Team	X
Dr Omar Shaikh	Clinical Lead GP for Medicines Management, St Helens CCG	
Paul Skipper	Deputy Director of Pharmacy The Royal Liverpool & Broadgreen University Hospitals NHS Trust	X
Dr Octavia Stevens	GP, Southport & Formby CCG	
Dave Thornton	Assistant Clinical Director of Pharmacy, University Hospital Aintree	X
Dr Matthew Van Miert	Consultant Anaesthetist, Wirral University Teaching Hospitals NHS FT	X
Debra Walker	Head of Pharmacy, Alder Hey Children's NHS Foundation Trust	
Mike Welsby	Pharmacist, St Helens & Knowsley Teaching Hospitals NHS Trust	X
John Williams	Acting Chief Pharmacist, Southport & Ormskirk Hospital NHS Trust	
Catherine Witter	Pharmacist, Southport & Ormskirk Hospital NHS Trust	
Attendees	Organisation(s)	Present
Carolyn Fogarty	Pharmacist, St Helens CCG	X
Anne Henshaw	Senior Medicines Commissioning Pharmacist, MLCSU	X
Joanne McEntee	Senior Medicines Information Pharmacist, North West Medicines Information Centre	X
Graham Reader	Senior Medicines Commissioning Pharmacist, MLCSU	X

APC/18/41	Welcome and apologies	Action
	The Chair welcomed members and accepted apologies for the following: Nicola Cartwright (Nigel Cosford attending), Dr Octavia Stevens, Sarah Quinn (Kathryn Phillips attending), Dr Omar Shaikh, Dr Patricia Cunningham, Dr Rob Barnett, Dr Ivan Camphor and John Williams.	
APC/18/42	Declarations of Interest and Quoracy Check	
	There were no declarations of interest. The meeting was quorate.	
APC/18/43	Minutes of the previous meeting and matters arising	
	<p>APC/18/43/01 – Minutes from the Previous Meeting The Minutes were agreed to be an accurate record of the previous meeting on 25 April 2018.</p> <p>APC/18/43/02 – Matters Arising Appendix 2 proposed amendments (Item ref APC/18/25/05) The committee had requested that the shared care subgroup consider if the document could be stand-alone. The shared care subgroup felt that there would be some benefits to this such as saving paperwork but there were also concerns about how best to present the appendix whilst making it clear that the full shared care framework was also available. It was agreed that this would be for local negotiation and implementation and that CCGs would need to inform the CSU how they wish the documents to be displayed on the website. The committee agreed this approach.</p> <p>Silk Garments (Item ref APC/18/26/02) This was discussed at the CCG Leads meeting, and it was proposed that the issue was raised at the Alder Hey Contract Review Meeting. CB informed the committee that there is no dispensing of silk garments through the hospital pharmacy and on review of the hospital FP10 prescribing, there appears to be</p>	



	<p>very little prescribing overall, but there is a possibility that GPs have been written to directly recommending prescribing in the past. The APC recommendation has been disseminated to the Dermatology team.</p> <p>NW Coast Palliative Care Symptoms Guideline (Item ref APC/18/26/05 matters arising) The previous iteration of this guideline had been linked to from the APC website, but when the updated guideline was brought to the APC it was proposed that there needed to be a discussion among CCG Medicines Management Leads as there are some local CCG guidelines now available. The CCG Leads agreed that a link to the updated NWC guideline could be added to the APC website, but additionally the links to local guidelines would be added, and it would be made clear which guidelines should be used in each CCG. If CCGs send links to any local guidelines to the CSU they will be added to the Pan Mersey formulary alongside the NWC guideline link.</p> <p>Dementia Prescribing Support Information – update (Item ref APC/18/25/01) It was agreed at the April APC that the shared care subgroup would remove the recommendation to stop donepezil 2-3 weeks before surgery. The subgroup decided that as this was primary prescribing support information, there was no need for the whole section on stopping drugs prior to surgery, as this would be addressed by the anaesthetist. Therefore, this section has been removed and the updated document will be uploaded to the website. There were no objections to this approach.</p> <p>Minor Formulary updates (raised under Item ref APC/18/37/01) There was some discussion at the April APC around how a decision is made by FGSG when a minor formulary amendment is proposed, whether it is added to the consultation for noting only or requires full consultation. This was discussed at the Chief Pharmacists and CCG Medicines Management Leads meeting, and it was agreed that this is a robust practice and that the subgroups should be supported to exercise discretion in this. It was agreed however that the consultation response form should now include a section where comments on items for noting could be added if consultees wanted to despite the subgroup not actively seeking consultation feedback.</p>	
APC/18/44	New Medicines	
	<p>APC/18/44/01 – Non-renewal of expiring statements The committee agreed with the NMSG proposals regarding the following:</p> <ul style="list-style-type: none"> • ALBIGLUTIDE subcutaneous injection (Eperzan® ▼) has been discontinued so the formulary entry will be deleted. • EVOLOCUMAB (Repatha® ▼) subcutaneous injection - statement will be archived when it expires and link to the NICE TA will be retained in the formulary. • DULAGLUTIDE subcutaneous injection (Trulicity® ▼) – established into clinical practice and sufficient information in formulary so statement will not be renewed. • LIRAGLUTIDE subcutaneous injection (Victoza®) AS MONOTHERAPY - no expression of interest received within 2 years so Grey statement will be archived and the drug remain as Grey in the formulary. 	



APC/18/45	Formulary and Guidelines	
	<p>APC/18/45/01- Freestyle Libre</p> <p>The initial draft policy statement was considered at January APC and was agreed, with several minor changes and a change in RAG designation from Red to Amber-initiated. The APC agreed that before this could be formally approved it was necessary to agree template documentation containing wording that could be used by organisations in their documentation to support specialist diabetes service providers and primary care in initiating, reviewing and continuing prescribing of Freestyle Libre in line with the agreed criteria in the statement, and this was subsequently consulted on.</p> <p>The consultation feedback on the template documentation (initiation criteria confirmation template, continuation criteria confirmation template, patient explanation template and primary care information template) was reviewed by the Committee.</p> <p>There were requests to add ‘and carer’ to point 1 of the statement, and to separate the information regarding unsuitability for use in driving from point 1 of the statement and place it further down the page, which the committee agreed should be made.</p> <p>Several amendments to the patient explanation template were agreed:</p> <ul style="list-style-type: none">-it is a patient contract, and should be named as such-it should mention the restriction to use in Type 1 diabetes-the symbol “>2” should be written as “greater than 2”-the wording “(excluding those required by DVLA requirements to confirm suitability to drive, or needed for management of intercurrent illness, mealtime BG tests for bolus calculator users, or tests for hypoglycaemia)” should be added to Point 1 regarding requirement for blood glucose monitoring 8 or more times daily, so as to be consistent with the section below this that lists criteria that will be needed to be fulfilled to continue to receive prescriptions which includes this wording. This also makes this template consistent with the initiation criteria confirmation and continuation criteria confirmation templates. <p>It was also queried if the patient contract template had been considered by a clear English group or patient group, but this had not occurred to date. It was agreed that the information would be agreed as it stands to enable the use of Freestyle Libre to be implemented, but work could be undertaken to ensure that the information meets the required standards in the future.</p> <p>The policy statement and all four template documents were approved by the APC with the above alterations.</p> <p>It was suggested that any practical implementation of the introduction of Freestyle Libre would likely occur from late June/ early July, taking into consideration provider specialist diabetes service readiness, readiness of community pharmacies to obtain supplies, and CCG processes to ratify the APC recommendation. It was agreed that the CSU would email out weekly updates to provider organisations advising of current CCG approvals as they were informed of these by CCGs, until all approvals were received.</p> <p>APC/18/45/02 – Grey statement – for noting</p> <p>Tiotropium (Spiriva Respimat) 2.5microgram, inhalation solution has now been licensed as add-on maintenance bronchodilator treatment in patients aged 6</p>	



years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year (previously licensed in adults only). A grey statement for this additional indication has been produced pending a formulary application. This was noted by the APC.

APC/18/45/03 – Gluten-free foods – Pan Mersey guideline withdrawal

There is now a national recommendation on NHS prescription of gluten-free foods, therefore this guideline will be withdrawn. Halton CCG have requested, however, that it is left on the website until a local policy is in place in Halton and they inform the CSU when it can be removed. This was agreed.

APC/18/45/04 – Guideline review-by dates – extension

Blood glucose and ketone meters and testing strips: This was deferred with a request that further discussion is required at the next CCG Medicines Management Leads meeting.

Headache pathway (adults): It was agreed that this guideline required some review before its review-by date can be extended, as it was agreed that the wording around sodium valproate in women of child-bearing age requires strengthening in light of additional MHRA advice issued in April.

APC/18/45/05 – Botulinum toxin in anal fissure – statement review

This statement has been reviewed and updated (no significant changes necessary) to ensure that the statement and Commissioning Policy, which has been reviewed, are consistent. This was agreed.

APC/18/45/06 – Potassium hydroxide statement – static list

The statement has been reviewed at its review-by date, and no changes are required. The committee agreed this, and that it be added to the static list.

APC/18/45/07 – Minor formulary amendments

Alendronic acid dispersible tablets: Addition to formulary was agreed.

Skudexa® (tramadol + dexketoprofen): Addition of Black designation in formulary agreed.

Duraphat® toothpaste RAG category: Change from Green to Amber Recommended designation agreed, for consistency with previously agreed Pan Mersey Guidance for Dental Prescribing in Primary Care.

Bisoprolol 3.75mg, 7.5mg tablets: Addition to formulary agreed.

Methylphenidate m/r – brands: Agreed that brands of methylphenidate m/r should no longer be listed in formulary.

Glyceryl trinitrate ointment: Rationalisation of formulary preparations - removal of 0.05% and 0.1% agreed; designation of 0.2% as Green in adults agreed.

Magnesium hydroxide mixture 8%: Addition to formulary for use in constipation in palliative care in line with NW Coast Palliative Care Symptoms Guideline agreed.

Octenisan® (octenidine): Addition to formulary of nasal gel and wash lotion agreed, as alternative to Bactroban in light of long-term supply difficulties with the latter.



APC/18/46	APC Reports	
	APC/18/46/01 – NICE TA Adherence Checklist April 2018 The checklist has been updated to the end of April 2018 and it was presented to the APC for noting.	
APC/18/47	Any Other Business	
	None	
APC/18/48	Date, Time and Venue for the next meeting	
	<u>Date and time of next APC meeting:</u> The next meeting will be on Wednesday 27 June 2018 at 2.00-4.00pm <u>Venue:</u> The Education Centre, Kent Lodge, Broadgreen Hospital, Liverpool, L14 3LB	

The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.